Anti-PD-1 Therapy-Associated Perforating Colitis by Romulo Celli, Harriet M. Kluger, Xuchen Zhang

Get full text

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab by Agnish Dey, Matthew Austin, Harriet M. Kluger, Nataliya Trunova, Helen Mann, Norah Shire, Claire Morgan, Diansong Zhou, Ganesh M. Mugundu

Get full text

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development by Jeffrey Sosman, Elad Sharon, Theresa LaVallee, Hussein A Tawbi, Ryan J Sullivan, Harriet M Kluger, Naiyer A Rizvi, David Feltquate

Get full text

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma by Mario Sznol, Harriet M. Kluger, Nicholas D. Klemen, Melinda Wang, Kelly Olino, James Clune, Stephan Ariyan, Sarah A. Weiss, Charles Cha, Jill C. Rubinstein

Get full text

Longitudinal single-cell analysis of a patient receiving adoptive cell therapy reveals potential mechanisms of treatment failure by Rihao Qu, Yuval Kluger, Junchen Yang, Jun Zhao, David A. Hafler, Diane S. Krause, Alexey Bersenev, Marcus Bosenberg, Michael Hurwitz, Liliana Lucca, Harriet M. Kluger

Get full text

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma by Thuy T. Tran, Jasmine Caulfield, Lin Zhang, David Schoenfeld, Dijana Djureinovic, Veronica L. Chiang, Victor Oria, Sarah A. Weiss, Kelly Olino, Lucia B. Jilaveanu, Harriet M. Kluger

Get full text

Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy by Sandra Martinez-Morilla, Myrto Moutafi, Aileen I. Fernandez, Shlomit Jessel, Prajan Divakar, Pok Fai Wong, Rolando Garcia-Milian, Kurt A. Schalper, Harriet M. Kluger, David L. Rimm

Get full text

Immunotherapy utilization in stage IIIA melanoma: less may be more by Alexander E. Frey, Daniel M. Kerekes, Sajid A. Khan, Thuy T. Tran, Harriet M. Kluger, James E. Clune, Stephan Ariyan, Mario Sznol, Jeffrey J. Ishizuka, Kelly L. Olino

Get full text

Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma by Ruth Halaban, Kelly Olino, James Clune, David L Rimm, Harriet M Kluger, Dijana Djureinovic, Wael Ibrahim, Raymond Baumann, Anjela Galan, David G Su, David A. Schoenfeld, Raysa Cabrejo, Sajid A Khan

Get full text

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy by Natalie J. Miller, Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, Shailender Bhatia, Lisa Lundgren, Martin A. Cheever, Suzanne L. Topalian, Paul Nghiem

Get full text

Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade by Ioannis A. Vathiotis, Leonidas Salichos, Sandra Martinez-Morilla, Niki Gavrielatou, Thazin Nwe Aung, Saba Shafi, Pok Fai Wong, Shlomit Jessel, Harriet M. Kluger, Konstantinos N. Syrigos, Sarah Warren, Mark Gerstein, David L. Rimm

Get full text

ScRNA-seq defines dynamic T-cell subsets in longitudinal colon and peripheral blood samples in immune checkpoint inhibitor-induced colitis by Clara Abraham, Marie E Robert, Harriet M Kluger, Lilach Aizenbud, Kevan C Herold, Matthew R Austin, Jacqueline E Mann, Ross D Merkin, Liliana Lucca, Badr Al Bawardy, Khadir Raddassi, Nikhil S Joshi, David A Hafler

Get full text

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases by Wei Wei, Michael Hurwitz, Sabina Signoretti, Lucia Jilaveanu, Toni K Choueiri, David L Rimm, Adebowale Adeniran, Sandra Martínez, Harriet M Kluger, David A Schoenfeld, Myrto Moutafi, Dijana Djureinovic, Ross D Merkin, David A Braun, Fabio Parisi

Get full text

Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes by Ana Luisa Perdigoto, Songyan Deng, Katherine C. Du, Manik Kuchroo, Daniel B. Burkhardt, Alexander Tong, Gary Israel, Marie E. Robert, Stuart P. Weisberg, Nancy Kirkiles-Smith, Angeliki M. Stamatouli, Harriet M. Kluger, Zoe Quandt, Arabella Young, Mei-Ling Yang, Mark J. Mamula, Jordan S. Pober, Mark S. Anderson, Smita Krishnaswamy, Kevan C. Herold

Get full text

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better by Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, David Schoenfeld, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia B. Jilaveanu, Harriet M. Kluger

Get full text

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce by Mario Sznol, Roberta Zappasodi, Margaret K. Callahan, Dung T. Le, Robert L. Ferris, James L. Gulley, Charles G. Drake, Ryan J. Sullivan, Elad Sharon, Hussein A. Tawbi, Harriet M. Kluger, Janis M. Taube, Shilpa Gupta, Suzanne L. Topalian, Edward Cha, Michael A. Postow, Vassiliki A. Papadimitrakopoulou, Maria L. Ascierto, Michaela Bowden, Helen X. Chen, David M. Feltquate, Rachel W. Humphrey, Theresa M. LaVallee, Vanessa M. Hubbard-Lucey, Eric H. Rubin

Get full text